Age-related differences in disease characteristics and clinical outcomes in polycythemia vera

Brady L. Stein*, Santosh Saraf, Urszula Sobol, Anna Halpern, Jamile Shammo, Damiano Rondelli, Laura Michaelis, Olatoyosi Odenike, Alfred Rademaker, Anaadriana Zakarija, Brandon J McMahon, Jerry L. Spivak, Alison R. Moliterno

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

57 Scopus citations


The natural history and prognosis for young patients with polycythemia vera (PV) in the post-JAK2 V617F era are not well defined. Therefore, we retrospectively analyzed disease characteristics and clinical outcomes in 120 patients ≤ 45 years and 84 patients ≥ 65 years at diagnosis. Despite lower white blood counts (9.2 vs. 13.4 × 109/L, p = 0.004) and a lower JAK2 V617F allele burden (51% vs. 66%, p = 0.015), younger patients with PV had comparable rates of vascular complications compared to older patients (27% vs. 31%, p = 0.64). However, splanchnic vein thrombosis occurred more frequently in younger patients (13% vs. 2%, p = 0.0056). Myelofibrotic and leukemic transformation, the most serious complications of myeloproliferative neoplasms (MPN), occurred with similar frequencies in young versus older patients (15% vs. 10%, p = 0.29). Prevention or delay of these complications is currently the most urgent challenge in the care of younger patients with PV.

Original languageEnglish (US)
Pages (from-to)1989-1995
Number of pages7
JournalLeukemia and Lymphoma
Issue number9
StatePublished - Sep 2013


  • JAK2 V617F
  • Myeloproliferative neoplasm
  • Polycythemia
  • Splanchnic vein thrombosis
  • Vera
  • Young

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Age-related differences in disease characteristics and clinical outcomes in polycythemia vera'. Together they form a unique fingerprint.

Cite this